Tumor-associated macrophages (TAMs) within the tumor microenvironment (TME) exhibit significant metabolic dysregulation, ...

Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in ...

Researchers showed that an experimental therapy indirectly converted suppressive immune cells into tumor-fighting cells. This ...

Worth up to $7 billion, Lilly’s second recent acquisition of a company in the space is centered around a cell therapy that’s ...

Eli Lilly announced Monday that it is acquiring Kelonia Therapeutics, a developer of gene therapies with a particular focus ...

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products, today announced upcoming presentations at the ...

A single-atom nanozyme mimicking cytochrome c oxidase restores mitochondrial energy production in stem cells, shifting their ...

Researchers from the Keck School of Medicine of USC have made an important advance toward understanding—and potentially ...

First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients ...

Plant cells do not easily abandon their mature identity. In apple, that transformation is especially important because somatic embryogenesis underpins ...

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced data from an investigator-initiated Phase II trial at Memorial Sloan Kettering Cancer Center, investigating ...

Pharmaceutical powerhouse Eli Lilly & Co. will buy Boston gene therapy maker Kelonia Therapeutics for at least $3.25 billion, ...